Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Irvine

Showing results (441-450 of 487) with videos related to

Pageof 49
Sort By:
JAAD International|November 17, 2022
Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin typesAngela L Bosma, Wouter Ouwerkerk, Madeline J Heidema, et al.
Skin Health and Disease|June 30, 2025
A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocolElizaveta Gribaleva, Niels Steen Krogh, David Prieto-Merino, et al.
The Journal of Allergy and Clinical Immunology|March 8, 2011
Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergySara J Brown, Yuka Asai, Heather J Cordell, et al.
The British Journal of Dermatology|July 24, 2024
A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR registerHelen Alexander, Rayka Malek, David Prieto-Merino, et al.
Nature Genetics|August 27, 2013
Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wastingLiat Samuelov, Ofer Sarig, Robert M Harmon, et al.
The Journal of Investigative Dermatology|August 14, 2016
Blue Rubber Bleb Nevus (BRBN) Syndrome Is Caused by Somatic TEK (TIE2) MutationsJulie Soblet, Jaakko Kangas, Marjut Nätynki, et al.
The Journal of Allergy and Clinical Immunology|September 9, 2008
Analysis of the individual and aggregate genetic contributions of previously identified serine peptidase inhibitor Kazal type 5 (SPINK5), kallikrein-related peptidase 7 (KLK7), and filaggrin (FLG) polymorphisms to eczema riskStephan Weidinger, Hansjörg Baurecht, Stefan Wagenpfeil, et al.
The British Journal of Dermatology|September 18, 2023
Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trialCarsten Flohr, Anna Rosala-Hallas, Ashley P Jones, et al.
The Journal of Investigative Dermatology|July 9, 2016
AP1S3 Mutations Cause Skin Autoinflammation by Disrupting Keratinocyte Autophagy and Up-Regulating IL-36 ProductionSatveer K Mahil, Sophie Twelves, Katalin Farkas, et al.
The Journal of Allergy and Clinical Immunology|January 15, 2019
Report from the National Institute of Allergy and Infectious Diseases workshop on "Atopic dermatitis and the atopic march: Mechanisms and interventions"Wendy F Davidson, Donald Y M Leung, Lisa A Beck, et al.
Pageof 49

Showing results (441-450 of 487) with videos related to

Sort By:
Pageof 49
JAAD International|November 17, 2022
Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin typesAngela L Bosma, Wouter Ouwerkerk, Madeline J Heidema, et al.
Skin Health and Disease|June 30, 2025
A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocolElizaveta Gribaleva, Niels Steen Krogh, David Prieto-Merino, et al.
The Journal of Allergy and Clinical Immunology|March 8, 2011
Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergySara J Brown, Yuka Asai, Heather J Cordell, et al.
The British Journal of Dermatology|July 24, 2024
A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR registerHelen Alexander, Rayka Malek, David Prieto-Merino, et al.
Nature Genetics|August 27, 2013
Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wastingLiat Samuelov, Ofer Sarig, Robert M Harmon, et al.
The Journal of Investigative Dermatology|August 14, 2016
Blue Rubber Bleb Nevus (BRBN) Syndrome Is Caused by Somatic TEK (TIE2) MutationsJulie Soblet, Jaakko Kangas, Marjut Nätynki, et al.
The Journal of Allergy and Clinical Immunology|September 9, 2008
Analysis of the individual and aggregate genetic contributions of previously identified serine peptidase inhibitor Kazal type 5 (SPINK5), kallikrein-related peptidase 7 (KLK7), and filaggrin (FLG) polymorphisms to eczema riskStephan Weidinger, Hansjörg Baurecht, Stefan Wagenpfeil, et al.
The British Journal of Dermatology|September 18, 2023
Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trialCarsten Flohr, Anna Rosala-Hallas, Ashley P Jones, et al.
The Journal of Investigative Dermatology|July 9, 2016
AP1S3 Mutations Cause Skin Autoinflammation by Disrupting Keratinocyte Autophagy and Up-Regulating IL-36 ProductionSatveer K Mahil, Sophie Twelves, Katalin Farkas, et al.
The Journal of Allergy and Clinical Immunology|January 15, 2019
Report from the National Institute of Allergy and Infectious Diseases workshop on "Atopic dermatitis and the atopic march: Mechanisms and interventions"Wendy F Davidson, Donald Y M Leung, Lisa A Beck, et al.
Pageof 49